Global Continuous Renal Replacement Therapy (CRRT) Market is Estimated to Grow at A CAGR of 7.2%

Date: 2015-10-29

The global CRRT market is estimated to grow at a CAGR of 7.2% from 2015 to 2020. Although mature markets such as the U.S., Germany, and the U.K. held larger shares in the CRRT market in 2015, Asia-Pacific is poised to grow at the highest CAGR of 8.7% in the next five years. Factors such as increasing aging population, rise in sepsis cases, growing focus of multinational companies on emerging markets, improvements in and the modernization of healthcare infrastructure, and high incidences of AKI cases in this region are propelling the growth of this market.

The overall growth of the CRRT market is driven by factors such as the rising prevalence of AKI, increasing prevalence of sepsis, growing number of ICU patients, rapid rise in aging population, clinical advantages of CRRT over intermittent blood purification techniques, and the preference for CRRT (it is held as a gold standard for the treatment of hemodynamically unstable patients). However, factors such as high complexity of therapy, high procedural cost of CRRT, stringent regulatory guidelines for CRRT in North America, and the dearth of trained ICU nurses are restraining the growth of this market. Moreover, emerging markets (such as China, India, Brazil, and Mexico); broadening application horizons of CRRT, ongoing researches to establish the safety and efficacy profile of CRRT, and the development of a CRRT system for pediatric patients are creating opportunities for the players involved in the market.

In this report, the global CRRT market has been segmented on the basis of product [CRRT systems, CRRT disposables (hemofilters, bloodlines, and other disposables), and dialysate and replacement fluids] and modality [slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF)].     

Geographically, Europe (comprising Germany, France, the U.K., and Rest of Europe) commanded the largest share of 41% of the global CRRT market in 2015, followed by North America. The European CRRT market is primarily driven by various factors such as the increasing cases of AKI in this region and rising aging population, approvals for CRRT machines and anti-coagulating agents in Europe for multiple applications, high utilization rate of CRRT products in Europe, prescription of CRRT products by intensivists in Europe, and research studies and controlled clinical trials to obtain efficacy and safety profile of CRRT products. However, the inconsistent reimbursement scenario for CRRT procedure across European countries is one of the major factors restraining the growth of the CRRT market in this region. 

The global CRRT market is highly consolidated in nature. Baxter International Inc. (U.S.) dominated the global CRRT market, with a share of ~55% in 2014, followed by Fresenius Medical Care AG & Co. KGaA (Germany). Other players include Asahi Kasei Medical Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), Infomed SA (Switzerland), Medica S.p.A (Italy), Medical Components, Inc. (U.S.), Nikkiso Co., Ltd (Japan), NxStage Medical, Inc. (U.S.), and Toray Medical Company Limited (Japan). Product approvals, launches, and enhancements; acquisition; and geographical expansion are the major strategies adopted by market players to achieve growth in the CRRT market.   


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample